A Study of Sofe-M in Participants With Selected Advanced Solid Tumors
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
The purpose of this study is to find out whether the study drug, Sofetabart Mipitecan (LY4170156), is safe, tolerable and effective in participants with advanced solid tumors. The study is conducted in three parts - phase Ia (dose-escalation, dose-optimization), phase Ib (dose-expansion), and phase 2 (dose expansion). The study will last up to approximately 5 years.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Diagnoza jednego z wymienionych typów nowotworu: rak jajnika, rak endometrium, rak szyjki macicy, rak płuca, rak piersi trojanegacyjny, rak trzustki lub rak jelita grubego
- •Nowotwór musi być w zaawansowanym stadium
✗ Disqualifies
- •Przerzuty do mózgu, które nie są kontrolowane
- •Historia zapalenia opon mózgowych spowodowanego rakiem
- •Aktywne, niekontrolowane infekcje bakteryjne, wirusowe, grzybiczne lub pasożytnicze
- •Problemy z rogówką oka lub przeszczep rogówki w przeszłości
- •Ciężkie działania niepożądane z poprzedniego leczenia
- •Poważne choroby serca
- •Ciąża, karmienie piersią lub planowanie karmienia podczas badania
- •Historia zapalenia płuc lub chorób śródmiąższowych płuc
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- October 7, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (25)
HonorHealth
Scottsdale, United States
University of California, San Diego (UCSD) - Moores Cancer Center
La Jolla, United States
Emory University
Atlanta, United States
South Texas Accelerated Research Therapeutics (START) Midwest
Grand Rapids, United States
NYU Langone Health - Long Island
Mineola, United States
New York University (NYU) Clinical Cancer Center
New York, United States
David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center
New York, United States
The Ohio State University (OSU) Wexner Medical Center
Columbus, United States
The University of Texas - MD Anderson Cancer Center
Houston, United States
START Mountain Region
West Valley City, United States
Inova Schar Cancer Institute
Falls Church, United States
Cancer Research SA
Adelaide, Australia
Icon Cancer Centre South Brisbane
QLD, Australia
Centre Leon Berard
Lyon, France
Institut de Cancerologie de l'Ouest - site St-Herblain
Saint-Herblain, France
Oncopole Claudius Regaud
Toulouse, France
Humanitas San Pio X
Milan, Italy
Istituto Europeo di Oncologia
Milan, Italy
Shizuoka Cancer Center
Shizuoka, Japan
National Cancer Center Hospital
Tokyo, Japan
Cancer Institute Hospital of JFCR
Tokyo, Japan
National Cancer Center
Goyang-si Gyeonggi-do, South Korea
Hospital Universitario Vall d'Hebron
Barcelona, Spain
Hospital Universitario 12 de Octubre
Madrid, Spain
Hospital Clinico Universitario de Valencia
Valencia, Spain
Trial contact
Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
Physicians interested in becoming principal investigators please contact
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 9/5/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.